Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several pharmacology/indication/supine hypertension statements align with the provided label sections, but some interaction and availability claims cannot be verified against the supplied labeling text, and the dataset does not allow assessment of key safety labeling areas (e.g., boxed warning/contraindications/pregnancy/children) or many dosing details.
Category Scores
Accurate Statements
Midodrine tablets are used to treat symptomatic orthostatic hypotension (low blood pressure when standing).
INDICATIONS AND USAGE
Midodrine raises standing blood pressure.
MECHANISM OF ACTION
Midodrine is a prodrug that is converted in the body to its active form.
PHARMACOKINETICS; MECHANISM OF ACTION
The active form of midodrine constricts blood vessels (vasoconstriction).
MECHANISM OF ACTION
Possible side effects of midodrine include supine hypertension (high blood pressure when lying down or at rest).
ADVERSE REACTIONS; SUPINE HYPERTENSION
A key safety concern with midodrine is supine hypertension.
ADVERSE REACTIONS; SUPINE HYPERTENSION
Clinicians may manage midodrine-related supine hypertension by adjusting dosing timing (for example, avoiding doses right before lying down).
DOSAGE AND ADMINISTRATION; INFORMATION FOR PATIENTS
Clinicians manage midodrine-related supine hypertension by monitoring blood pressure.
DOSAGE AND ADMINISTRATION; SUPINE HYPERTENSION
Unsupported Statements
Midodrine’s blood-pressure–raising effects can conflict with antihypertensive drugs.
The provided label text does not state or clearly support this specific claim (no direct antihypertensive drug interaction statement is present in the supplied sections).
Combination therapy with midodrine and antihypertensive drugs should be managed by a clinician to balance standing blood pressure improvement against the risk of high blood pressure at other times of day.
No supplied label text supports this specific balancing/antihypertensive combination management claim.
Midodrine is commonly available as a generic in tablet form, depending on the country and market.
The provided FDA-label sections do not address generic availability/market dependence; this cannot be evaluated for label alignment.
Contradictions
Important Omissions
Full dosage regimen and constraints (e.g., recommended 10 mg TID, dosing interval/last dose not later than 6 P.M., not more frequently than every ~3 hours, and not giving doses after evening meal or <4 hours before bedtime) were not provided.
Importance:
Moderate
Key dose–response/safety thresholds (e.g., high rate of severe/persistent supine hypertension at 20 mg; total daily dose >30 mg safety not systematically studied; discontinue only if significant symptomatic improvement) were not addressed.
Importance:
Moderate
Renal-function dosing caution (desglymidodrine excreted renally; start with 2.5 mg in abnormal renal function) and the statement that dosing in children is not adequately studied were not addressed.
Importance:
Moderate
Headache as a blood-pressure-elevation sign was not clearly supported; the label lists headache as an adverse reaction but does not explicitly frame it as a 'sign of elevated blood pressure.'
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
While the major on-label risk of supine hypertension and related monitoring/timing concepts are included, the response omits several specific dosing/safety constraints and does not reliably establish the claimed antihypertensive-related interaction language, which could mislead regarding medication management outside the provided label-supported interaction statements.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Two interaction claims and a generic-availability claim are not supported by the supplied label text, and multiple dosing specifics/safety thresholds are omitted.
Suggested Improvement
Restrict interaction/combination statements to those explicitly supported by the provided 'Drug Interactions' and include label-specific dosing timing/limits and monitoring/discontinuation criteria for supine hypertension.